Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novo Nordisk A/S
Age
18–74
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Signed consent (general consent for research or study-specific informed consent) obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
Male or female, aged 18 to 74 years (both inclusive) at the time of Saxenda® initiation.
Have been prescribed Saxenda® for weight management.
For the reimbursed cohort, per the Swiss reimbursement criteria: BMI greater than or equal to 35 kg/m\^2 or a BMIgreater than or equal to 28 and below 35 kg/m\^2 with additional weight related comorbidities (pre diabetes or T2D (Type 2 Diabetes Mellitus), hypertension, dyslipidaemia), prior to receiving the Saxenda® treatment.
For the non-reimbursed cohort, BMI greater than or equal to 30 kg/m\^2 or a BMI greater than or equal to 28 kg/m\^2 with additional weight related comorbidities (pre diabetes or T2D, arterial hypertension, dyslipidaemia), prior to receiving the Saxenda® treatment.
The decision to initiate treatment with commercially available Saxenda® has been made by the patient/legally acceptable representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
Baseline weight measurement within 3 months of Saxenda® initiation/prescription.
At least one weight assessment post-Saxenda® initiation/prescription.
You may not be if
Previous participation in this study. Participation is defined as having given informed consent in this study.
Treatment with any investigational drug within 30 days of Saxenda® prescription/initiation.
Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.
Concomitant treatment of Saxenda® with other GLP 1 (Glucagon-like peptide-1) receptor agonists, or orlistat.
Concomitant treatment with sodium/glucose cotransporter-2 inhibitors (SGLT 2i), dipeptidyl peptidase-4 (DPP 4i), or insulin for the reimbursed cohort only.
Patients who have been treated with any obesity medication for last 12 weeks prior to initiation of Saxenda® treatment.
Patients who have previously been treated with a GLP 1 receptor agonist for the reimbursed cohort only.
Patients who have undergone bariatric surgery at any time before starting Saxenda® treatment.
Patients initiating Saxenda® treatment after 31 October 2020.
Clareo Health | A Research Study About Weight Loss and Treatment Patterns With the Use of Saxenda® in Adults in Real-life Settings in Switzerland
